Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 622

Similar articles for PubMed (Select 22662154)

1.

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.

Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.

PLoS One. 2012;7(5):e37431. doi: 10.1371/journal.pone.0037431. Epub 2012 May 25.

2.

The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells.

Li C, Xin P, Xiao H, Zheng Y, Huang Y, Zhu X.

Cancer Cell Int. 2015 Jun 24;15:65. doi: 10.1186/s12935-015-0213-1. eCollection 2015.

3.

The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.

Dogan Turacli I, Ozkan AC, Ekmekci A.

Tumour Biol. 2015 Jun 25. [Epub ahead of print]

PMID:
26108998
4.
5.

Targeted Inhibition of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity.

Durrant DE, Das A, Dyer S, Tavallai S, Dent P, Kukreja RC.

Mol Pharmacol. 2015 Jun 22. pii: mol.115.099143. [Epub ahead of print]

6.

Modulation of glucocorticoid resistance in pediatric T-cell Acute Lymphoblastic Leukemia by increasing BIM expression with the PI3K/mTOR inhibitor BEZ235.

Hall CP, Reynolds CP, Kang MH.

Clin Cancer Res. 2015 Jun 16. pii: clincanres.0114.2015. [Epub ahead of print]

PMID:
26080839
7.

Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models.

Üstün S, Lassnig C, Preitschopf A, Mikula M, Müller M, Hengstschläger M, Weichhart T.

Transpl Immunol. 2015 Jun 11. pii: S0966-3274(15)30004-6. doi: 10.1016/j.trim.2015.06.001. [Epub ahead of print]

PMID:
26073719
8.

Tumor-Targeted Synergistic Blockade of MAPK and PI3K From a Layer-by-Layer Nanoparticle.

Dreaden EC, Kong YW, Morton SW, Correa S, Choi KY, Shopsowitz KE, Renggli K, Drapkin R, Yaffe MB, Hammond PT.

Clin Cancer Res. 2015 Jun 1. pii: clincanres.0013.2015. [Epub ahead of print]

PMID:
26034127
9.

Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.

Inaba K, Oda K, Ikeda Y, Sone K, Miyasaka A, Kashiyama T, Fukuda T, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T.

Gynecol Oncol. 2015 May 29. pii: S0090-8258(15)30013-5. doi: 10.1016/j.ygyno.2015.05.031. [Epub ahead of print]

PMID:
26033306
10.

Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.

Garofalo C, Capristo M, Mancarella C, Reunevi H, Picci P, Scotlandi K.

Front Endocrinol (Lausanne). 2015 May 13;6:74. doi: 10.3389/fendo.2015.00074. eCollection 2015.

11.

LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.

Xiao P, Sun LL, Wang J, Han RL, Ma Q, Zhong DS.

Acta Pharmacol Sin. 2015 Jun 1. doi: 10.1038/aps.2015.19. [Epub ahead of print]

PMID:
26027660
12.

K-Ras stabilization by estrogen via PKCδ is involved in endometrial tumorigenesis.

Koo KH, Jeong WJ, Cho YH, Park JC, Min DS, Choi KY.

Oncotarget. 2015 May 8. [Epub ahead of print]

13.

Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations.

Bonelli MA, Cavazzoni A, Saccani F, Alfieri RR, Quaini F, La Monica S, Galetti M, Cretella D, Caffarra C, Madeddu D, Frati C, Lagrasta CA, Falco A, Rossetti P, Fumarola C, Tiseo M, Petronini PG, Ardizzoni A.

Mol Cancer Ther. 2015 May 26. pii: molcanther.0892.2014. [Epub ahead of print]

PMID:
26013318
14.

The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.

Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 May 14. [Epub ahead of print]

15.

MEK inhibitor PD-0325901 overcomes resistance to PI3K/mTOR inhibitor PF-5212384 and potentiates anti-tumor effects in human head and neck squamous cell carcinoma.

Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce M, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.

Clin Cancer Res. 2015 May 14. pii: clincanres.3377.2015. [Epub ahead of print]

PMID:
25977343
16.

PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer.

Wang H, Zhang L, Yang X, Jin Y, Pei S, Zhang D, Zhang H, Zhou B, Zhang Y, Lin D.

Oncotarget. 2015 Jun 10;6(16):14385-98.

17.

Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.

Matsushima M, Kikuchi E, Matsumoto K, Hattori S, Takeda T, Kosaka T, Miyajima A, Oya M.

Int J Oncol. 2015 Jul;47(1):377-83. doi: 10.3892/ijo.2015.2995. Epub 2015 May 11.

PMID:
25963317
18.
19.

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.

Echeverry N, Ziltener G, Barbone D, Weder W, Stahel RA, Broaddus VC, Felley-Bosco E.

Cell Death Dis. 2015 May 7;6:e1757. doi: 10.1038/cddis.2015.124.

PMID:
25950487
20.

Biphasic activity of chloroquine in human colorectal cancer cells.

Park D, Lee Y.

Balsaenggwa Saengsig. 2014 Dec;18(4):225-31. doi: 10.12717/devrep.2014.18.4.225.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk